Patients received once-monthly doses of the 1-month formulation of paliperidone palmitate ( 50 , 75 , 100 , or 150 mg eq ) during the transition phase , followed by a single dose of the 3-month formulation ( 3.5 times the stabilized dose of once-monthly paliperidone palmitate ) during the maintenance phase .